Infinity Pharmaceuticals Competitors

Amgen (NASDAQ:AMGN) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Institutional and Insider Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Amgen and Infinity Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Amgen and Infinity Pharmaceuticals, as provided by MarketBeat.

Amgen presently has a consensus target price of $261.1429, suggesting a potential upside of 0.77%. Infinity Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 223.74%. Given Infinity Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Infinity Pharmaceuticals is more favorable than Amgen.

Profitability

This table compares Amgen and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.

Summary

Amgen beats Infinity Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Volatility & Risk

Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Gilead Sciences and Infinity Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Gilead Sciences and Infinity Pharmaceuticals, as provided by MarketBeat.

Gilead Sciences presently has a consensus price target of $97.68, indicating a potential upside of 47.15%. Infinity Pharmaceuticals has a consensus price target of $9.00, indicating a potential upside of 223.74%. Given Infinity Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Infinity Pharmaceuticals is more favorable than Gilead Sciences.

Summary

Gilead Sciences beats Infinity Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Infinity Pharmaceuticals (NASDAQ:INFI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Infinity Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Infinity Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat.

Infinity Pharmaceuticals presently has a consensus target price of $9.00, suggesting a potential upside of 223.74%. Vertex Pharmaceuticals has a consensus target price of $293.2083, suggesting a potential upside of 33.18%. Given Infinity Pharmaceuticals' higher probable upside, analysts clearly believe Infinity Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

Infinity Pharmaceuticals has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

46.7% of Infinity Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 13.8% of Infinity Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Infinity Pharmaceuticals and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Infinity Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Regeneron Pharmaceuticals and Infinity Pharmaceuticals, as reported by MarketBeat.com.

Regeneron Pharmaceuticals presently has a consensus target price of $644.1739, suggesting a potential upside of 27.71%. Infinity Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 223.74%. Given Infinity Pharmaceuticals' higher probable upside, analysts clearly believe Infinity Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Infinity Pharmaceuticals' gross revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Infinity Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Analyst Ratings

This is a summary of current recommendations for Biogen and Infinity Pharmaceuticals, as reported by MarketBeat.com.

Biogen presently has a consensus target price of $303.3103, suggesting a potential upside of 11.02%. Infinity Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 223.74%. Given Infinity Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Infinity Pharmaceuticals is more favorable than Biogen.

Profitability

This table compares Biogen and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Biogen and Infinity Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500.

Summary

Biogen beats Infinity Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Infinity Pharmaceuticals (NASDAQ:INFI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Alexion Pharmaceuticals and Infinity Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 46.7% of Infinity Pharmaceuticals shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Alexion Pharmaceuticals and Infinity Pharmaceuticals, as provided by MarketBeat.com.

Alexion Pharmaceuticals presently has a consensus target price of $153.4286, indicating a potential downside of 7.87%. Infinity Pharmaceuticals has a consensus target price of $9.00, indicating a potential upside of 223.74%. Given Infinity Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Infinity Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Risk and Volatility

Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500.

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Infinity Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats Infinity Pharmaceuticals on 9 of the 15 factors compared between the two stocks.